Abstract: The disclosure provides a compound of formula (I) and pharmaceutical compositions thereof. The compound of formula (I) of the present disclosure can be used as a degradation agent of cyclin K (CyclinK protein), and can be used to prevent or treat diseases related to CyclinK protein.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: The invention provides a heat-storage medium conveying system for a solar-thermal power plant. The system includes a high-level tank subsystem including a high-level tank used to store the heat-storage medium. The system further includes a heat-storage medium transport subsystem. The high-level tank subsystem is connected with the heat-storage medium transport subsystem. The heat-storage medium transport subsystem includes a low-level tank. A mounting height of the low-level tank is lower than that of the high-level tank. A volume of the low-level tank is smaller than a volume of the high-level tank. The heat-storage medium can enter the low-level tank from the high-level tank partially or completely by its own gravity. The low-level tank is provided with a conveying pump, and the heat-storage medium is pumped out of the low-level tank through the conveying pump.

Abstract: Provided is a compound represented by formula (I) and a pharmaceutical composition thereof, as well as a method for using a compound represented by formula (I) to prevent and/or treat immune-related disorders.

Abstract: A combination therapy for treating PIK3CA-mutated cancer, comprising administering a PI3K inhibitor, a prostaglandin receptor (PGE2) inhibitor, and a PD-1 inhibitor to a subject in need thereof. The anti-tumor activity brought about by a three-drug combination method is significantly superior to that brought about by a two-drug combination method of the PI3K inhibitor and the PD-1 inhibitor, and the prostaglandin receptor (PGE2) and the PD-1 inhibitor.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: The present application provides pyrrolotriazine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.

Abstract: The present invention relates to a CSF1R inhibitor, and in particular to a highly active CSF1R inhibitor compound having the structure of formula (I). Said compound of the present invention has high inhibitory activity on CSF1R.

Abstract: Provided are a compound of Formula (I) and a pharmaceutical composition thereof, as well as a method for using the compounds of Formula (I) to prevent and/or treat immune-related disorders.

Abstract: A compound represented by formula (I) and a pharmaceutical composition thereof. The compound represented by formula (I) may be used as an adenosine receptor inhibitor, especially as an A2A and/or A2B inhibitor, for example, the compound may be used to prevent or treat diseases related to A2A and/or A2B activity or expression.

Abstract: The invention provides a heat-storage medium conveying system for a solar-thermal power plant. The system includes a high-level tank subsystem including a high-level tank used to store the heat-storage medium. The system further includes a heat-storage medium transport subsystem. The high-level tank subsystem is connected with the heat-storage medium transport subsystem. The heat-storage medium transport subsystem includes a low-level tank. A mounting height of the low-level tank is lower than that of the high-level tank. A volume of the low-level tank is smaller than a volume of the high-level tank. The heat-storage medium can enter the low-level tank from the high-level tank partially or completely by its own gravity. The low-level tank is provided with a conveying pump, and the heat-storage medium is pumped out of the low-level tank through the conveying pump.